ATLANTA, GA--(Marketwire - October 18, 2007) - AtheroGenics, Inc. (NASDAQ: AGIX), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, today announced the resignation of Rob Scott, M.D., Executive Vice President of Research & Development and Chief Medical Officer, to pursue other interests. Effective immediately, G. Alexander Fleming, M.D., will fill the post as Acting Chief Medical Officer. Dr. Fleming is President and Chief Executive Officer of Kinexum LLC, a prominent life sciences consulting firm, and is a former senior physician at the U.S. Food and Drug Administration and a recognized expert in diabetes therapeutic development.
